EGFL7 and colorectal carcinoma: Given the evidences that high EGFL7 expression led to poor prognostic events in CRC, and parsatuzumab studies did not show promisor results, the contribution of EGFL7 in CRC development, maintenance and metastization should be better investigated in order to propose more efficient treatment protocols.